Last reviewed · How we verify
AG chemotherapy
AG chemotherapy is a Chemotherapy combination regimen Small molecule drug developed by Zhejiang Cancer Hospital. It is currently in Phase 3 development for Cancer (specific indication not publicly detailed; Phase 3 trial ongoing at Zhejiang Cancer Hospital).
AG chemotherapy is a chemotherapeutic regimen combining doxorubicin and gemcitabine to inhibit cancer cell proliferation and induce apoptosis.
AG chemotherapy is a chemotherapeutic regimen combining doxorubicin and gemcitabine to inhibit cancer cell proliferation and induce apoptosis. Used for Cancer (specific indication not publicly detailed; Phase 3 trial ongoing at Zhejiang Cancer Hospital).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AG chemotherapy |
|---|---|
| Sponsor | Zhejiang Cancer Hospital |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The AG regimen combines doxorubicin, a topoisomerase II inhibitor that intercalates DNA and prevents strand separation, with gemcitabine, a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA to cause chain termination. Together, these agents work synergistically to damage cancer cell DNA and trigger apoptotic pathways.
Approved indications
- Cancer (specific indication not publicly detailed; Phase 3 trial ongoing at Zhejiang Cancer Hospital)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Cardiotoxicity
- Mucositis
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma (PHASE1, PHASE2)
- IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer (PHASE2)
- Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer (NA)
- HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation (PHASE2)
- LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study (PHASE1, PHASE2)
- Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma (PHASE2)
- Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AG chemotherapy CI brief — competitive landscape report
- AG chemotherapy updates RSS · CI watch RSS
- Zhejiang Cancer Hospital portfolio CI
Frequently asked questions about AG chemotherapy
What is AG chemotherapy?
How does AG chemotherapy work?
What is AG chemotherapy used for?
Who makes AG chemotherapy?
What drug class is AG chemotherapy in?
What development phase is AG chemotherapy in?
What are the side effects of AG chemotherapy?
Related
- Drug class: All Chemotherapy combination regimen drugs
- Manufacturer: Zhejiang Cancer Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Cancer (specific indication not publicly detailed; Phase 3 trial ongoing at Zhejiang Cancer Hospital)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing